The elevated breast cancer risk observed with zoledronic acid is explained by the fact that this drug irreversibly blocks also the Kir6.1-Sur1 subunits at higher concentrations (Maqoud et al., 2021). The gene discussed is KCNJ8; the disease is breast cancer.